Noureddine Boukhatem

Constitutional Oncogenetics


Скачать книгу

18 PRKAR1A / 1 2 Gorlin syndrome PTCH1 / 101 17 120 PTCH2 / 1 0 SUFU / 1 0 Li–Fraumeni syndrome TP53 / 31 39 71 CHEK2 / 1 0 Peutz–Jeghers syndrome STK11 / 12 9 21 Juvenile polyposis syndrome BMPR1A / 7 9 36 SMAD4 / 11 9 Werner syndrome WRN BI 1 0 3 MONO 0 2 Xeroderma pigmentosum XP BI 11 15 43 MONO 3 14

      COMMENT ON TABLE I.1.– Genes: names of the genes directly linked to the predisposition mentioned and which were reported in a diagnostic report, in France, in 2016. IC+: Index cases identified in 2016 as carriers of a genetic alteration in the genes mentioned; REL+: relatives identified in 2016 as carriers of a genetic alteration in the genes mentioned; AR: allelic status for genes with autosomal recessive transmission; BI: index or relatives carrying biallelic mutations; MONO: index or relatives carrying a monoallelic mutation; *constitutional hypermethylation of the promoter of the MLH1 gene; **CEBPA, ETV6, GATA2, KIT, MPL, SBDS, SH2B3, SRP72, WAS, etc.; ***BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, SOS1, SOS2, etc.

      DEFINITION.– DNA methylation is the enzymatically controlled addition of a methyl group to a nucleotide base (such as cytosine in eukaryotes) in a DNA molecule that plays a role in the regulation of gene expression (e.g., by inhibiting gene transcription).



Genetic predisposition to cancer *IC+ and REL+ % Rank
Breast ovarian syndrome (including isolated ovarian cancers) 4,356 52.62 1
Lynch syndrome 1,148 13.87 2
Neurofibromatosis 682 8.24 3
Familial adenomatous polyposis 528 6.38 4
Endocrine neoplasia 213 2.57 5
Hereditary paraganglioma–pheochromocytoma 184 2.22 6
Birt–Hogg–Dubé syndrome 167 2.02 7
RASopathies and Noonan syndrome 159 1.92 8
Familial malignant melanoma 120 1.45 9
Gorlin syndrome 120 1.45 10
Li–Fraumeni syndrome 71 0.86 11
Ataxia–telangiectasia 59 0.71 12
Hyperparathyroidism 51 0.62 13
Cowden syndrome 51 0.62 14
Fanconi syndrome 50 0.60